Topic Editors

1. FP-I3ID, Faculty of Health Sciences, University Fernando Pessoa, 4249-004 Porto, Portugal
2. Associate Laboratory i4HB, Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
3. UCIBIO, Applied Molecular Biosciences Unit, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050‐313 Porto, Portugal
UCIBIO, REQUIMTE, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal

Pharmacology and Toxicology of Amphetamine Type Stimulants

Abstract submission deadline
closed (30 April 2023)
Manuscript submission deadline
30 June 2023
Viewed by

Topic Information

Dear Colleagues,

Amphetamine type stimulants are worldwide known drugs abuse. According to the World Drug Report 2021 of the United Nations, in 2019, there were an estimated 27 million past-year users of amphetamines, including amphetamine (AMPH) and methamphetamine (METH), corresponding to 0.5 per cent of the global population aged 15–64. Also, nearly 20 million people globally are estimated to have used “ecstasy” (3,4-Methylenedioxymethamphetamine or MDMA) in the past year, corresponding to 0.4 per cent of the global population aged 15–64. These drugs target the brain to stimulate the release of monoamine neurotransmitters, which promote the central effects quested by drug users. However, these drugs have been associated to neurotoxicity, cardiovascular toxicity, as well as hepatic and renal toxicity, either acutely or chronically. Notwithstanding, amphetamines have been and are still used therapeutically, and nowadays new drug repurposing is being attempted. D-amphetamine (AMPH) and D,L-threo-Methylphenidate (MPH) psychostimulants are first-line pharmacotherapies for attention-deficit/hyperactivity disorder (ADHD). Also, MDMA assisted psychotherapy is being studied for the treatment of post-traumatic stress disorder (PTSD). Herein all aspects of the pharmacology and toxicology of amphetamine type stimulants are considered. This Topic aims to bring together the latest findings in the field of amphetamine type stimulants, from in vitro to pre-clinical studies or even clinical studies to identify novel mechanisms underlying their (neuro)pharmacology and toxicology, but also new targets for new clinical uses.

Prof. Dr. João Paulo Capela
Prof. Dr. Vera Marisa Costa
Topic Editors


  • drugs of abuse
  • amphetamine type stimulants (ATS)
  • methamphetamine (METH)
  • 3,4-Methylenedioxymethamphetamine (MDMA or “Ecstasy”)
  • methylphenidate (MPH)
  • attention-deficit/hyperactivity disorder (ADHD)

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Future Pharmacology
- - 2021 19.7 Days 1000 CHF Submit
- - 2020 17.1 Days 1000 CHF Submit
5.215 4.0 2004 15.6 Days 2200 CHF Submit
6.525 6.0 2009 15.9 Days 2600 CHF Submit
5.075 6.6 2009 14.6 Days 2400 CHF Submit

Preprints is a platform dedicated to making early versions of research outputs permanently available and citable. MDPI journals allow posting on preprint servers such as prior to publication. For more details about reprints, please visit

Published Papers

This Topic is now open for submission.
Back to TopTop